Skip to main content

ArriVent BioPharma, Inc.

corporate_fare Company Profile

ArriVent BioPharma, Inc.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed AVBP - Latest Insights

AVBP
Apr 28, 2026, 4:08 PM EDT
Filing Type: DEF 14A
Importance Score:
7
ArriVent BioPharma Files Definitive Proxy, Reveals Substantial Executive Compensation Increases
Sentiment: Neutral
View Wiseek Article
AVBP
Mar 17, 2026, 5:05 PM EDT
Filing Type: 8-K
Importance Score:
7
ArriVent BioPharma to Present Positive Preclinical Data for Firmonertinib and Novel ADC ARR-002 at AACR Meeting
Sentiment: Positive
View Wiseek Article
AVBP
Mar 05, 2026, 4:25 PM EST
Source: Wiseek News
Importance Score:
8
Net Loss Widens to $166.3M for ArriVent BioPharma in 2025, EPS $(4.32) on Higher R&D
Sentiment: Negative
View Wiseek Article
AVBP
Mar 05, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
ArriVent BioPharma Reports Strong Pipeline Progress, NMPA Approval, and Extended Cash Runway Despite Increased Net Loss
Sentiment: Positive
View Wiseek Article